TEMPO 3:4 (2012) — Trial Summary

TEMPO 3:4 (2012): Evaluated tolvaptan, a vasopressin V2-receptor antagonist, in autosomal dominant polycystic kidney disease (ADPKD).

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.